Search bioRxiv⌕ Search

bioRxiv · 10.64898/2025.12.02.691498

HID1 domain-containing protein 1 is required for normal cell proliferation in Schizosaccharomyces pombe

Abstract

HID1 domain-containing protein 1 (HID1) is a Golgi apparatus (GA) protein involved in the trafficking of cellular material. From reduced expression in cancer cell lines, it had been proposed to be a tumor suppressor in humans. In contrast, it is required for normal larval development of Caenorhabditis elegans, thereby raising an apparent contradiction for HID1 function regarding the inhibition or maintenance of cell proliferation. An extensive comparison of publicly available gene expression data revealed that HID1 transcript levels in cancer cell lines were not representative of those in primary tumors, and the gene is amplified in many primary tumors. These findings question the role for its expression to suppress cell proliferation. Subsequently, we employed the model S. pombe to explore the role of HID1 in cell proliferation. The knock-out mutant hid1{Delta} exhibited a reduced proliferation phenotype due to a prolonged lag-phase but, eventually, attained parent strain rates of apparent proliferation. RNAseq-based transcriptomics revealed that hid1{Delta} retained features of metabolically stressed cells with quiescence-like transcriptional regulation. A label-free proteomic analysis revealed a lack of various membrane proteins suggesting cells with compromised Golgi apparatus (GA) function. The inability of hid1{Delta} to grow on agar containing a standard minimal medium suggested a link to metabolic deficiency. These findings point to a hid1{Delta}-related perturbation in GA function that compromises cell recovery from metabolic change.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Fritsche, A.-p., Alasmari, A., Alshehri, M., Hooks, K. B., Claverol, S., Fuller, H., McFarlane, R. J., Hooks, M. A.. 2025-12-02. HID1 domain-containing protein 1 is required for normal cell proliferation in Schizosaccharomyces pombe. https://doi.org/10.64898/2025.12.02.691498

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗